U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood

Benzinga12/19 00:11

Daré Bioscience Announces Phase 3 Plans For Sildenafil Cream, 3.6%, In The Treatment Of Female Sexual Arousal Disorder; Daré's Sildenafil Cream Has The Potential To Receive The First FDA Approval For FSAD

Benzinga12/16 21:17

Daré Bioscience Announces Publication In Sexual Medicine Highlighting Positive Subgroup Findings From Phase 2b RESPOND Study Of Sildenafil Cream, 3.6%, For Female Sexual Arousal Disorder

Benzinga12/10 21:07

Press Release: Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Dow Jones12/04 21:00

Maxim Group LLCはデア・バイオサイエンス(DARE.US)のレーティングを中立に据え置き

Maxim Group LLCのアナリストJason McCarthyは$Dare Bioscience(DARE.US)$のレーティングを中立に据え置き。TipRanksのデータによると、このアナリストの最近1年間の的中率は27.8%、平均リターンは-14.6%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情報を提供している独立第三者で

Futuニュース11/16 23:32

Dare Bioscience Files to Sell 2.75M Shares of Common Stocks by Selling Shareholders

Seeking Alpha11/16 06:32